[go: up one dir, main page]

WO2012047017A3 - 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same - Google Patents

2,3-dihydro-isoindol-1-one derivative and a composition comprising the same Download PDF

Info

Publication number
WO2012047017A3
WO2012047017A3 PCT/KR2011/007370 KR2011007370W WO2012047017A3 WO 2012047017 A3 WO2012047017 A3 WO 2012047017A3 KR 2011007370 W KR2011007370 W KR 2011007370W WO 2012047017 A3 WO2012047017 A3 WO 2012047017A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
kinase activity
isoindol
dihydro
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/007370
Other languages
French (fr)
Korean (ko)
Other versions
WO2012047017A2 (en
Inventor
홍용래
이미정
김정미
홍장원
장호진
박수봉
이휘성
최종류
노성구
조중명
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE
CrystalGenomics Inc
Korea Health Industry Development Institute
Original Assignee
KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE
CrystalGenomics Inc
Korea Health Industry Development Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE, CrystalGenomics Inc, Korea Health Industry Development Institute filed Critical KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE
Publication of WO2012047017A2 publication Critical patent/WO2012047017A2/en
Publication of WO2012047017A3 publication Critical patent/WO2012047017A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition for the treatment, alleviation or prevention of diseases associated with abnormal or deregulated kinase activity, the composition comprising a compound represented by chemical formula 1 and a pharmaceutically acceptable salt, hydrate, prodrug or solvate thereof. The compound and composition of the present invention inhibit various types of protein kinase activity, and hence can be used to advantage in the treatment, alleviation or prevention of diseases associated with abnormal or deregulated kinase activity.
PCT/KR2011/007370 2010-10-05 2011-10-05 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same Ceased WO2012047017A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38995010P 2010-10-05 2010-10-05
US61/389,950 2010-10-05

Publications (2)

Publication Number Publication Date
WO2012047017A2 WO2012047017A2 (en) 2012-04-12
WO2012047017A3 true WO2012047017A3 (en) 2012-05-31

Family

ID=45928221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007370 Ceased WO2012047017A2 (en) 2010-10-05 2011-10-05 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same

Country Status (1)

Country Link
WO (1) WO2012047017A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3521291A1 (en) 2010-05-20 2019-08-07 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
RU2018138028A (en) * 2012-12-28 2019-03-21 Кристалдженомикс, Инк. Derivatives of 2,3-dihydro-isoindole-1-one and methods for their use as bruton tyrosine kinase inhibitors
KR20180041135A (en) 2015-07-16 2018-04-23 어레이 바이오파마 인크. A pyrazolo [1,5-a] pyridine compound substituted as a RET kinase inhibitor
KR101691954B1 (en) 2016-04-26 2017-01-02 고려대학교 산학협력단 Novel N-acylurea Derivatives and Composition for Prevention or Treatment of Cardiovascular Disorders Comprising the Same
CN105924387A (en) * 2016-04-28 2016-09-07 西安交通大学 Diarylurea compound with antitumor activity, and preparation method and application thereof
CN105859638B (en) * 2016-04-28 2018-07-17 西安交通大学 A kind of ring succinamide compound with anti-tumor activity and its preparation method and application
CN105906568A (en) * 2016-04-28 2016-08-31 西安交通大学 Cyclopropane diamide compound with antitumor activity and preparation method and application thereof
CN105924403B (en) * 2016-04-28 2018-07-17 西安交通大学 A kind of ring propane diamide compound with anti-tumor activity and its preparation method and application
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (en) 2017-01-18 2022-04-26 阿雷生物药品公司 Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors
EP3573978A1 (en) * 2017-01-25 2019-12-04 Basf Se Process for preparation of benzylic amides
TWI821174B (en) * 2017-02-21 2023-11-11 加拿大商艾普托斯生物科學公司 Methods for treating patients with hematolgic malignancies
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
TWI876442B (en) 2017-10-10 2025-03-11 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
WO2019134662A1 (en) * 2018-01-03 2019-07-11 南京明德新药研发股份有限公司 Heterocyclic compound as csf-1r inhibitor and use thereof
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TW201932464A (en) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN113365622A (en) * 2018-11-30 2021-09-07 艾普托斯生物科学公司 Combination therapy using 2, 3-dihydroisoindol-1-one compounds and methods for treating patients with various mutations
WO2021136345A1 (en) * 2019-12-30 2021-07-08 路良 Jak inhibitor compound and use thereof
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
WO2024261709A1 (en) * 2023-06-21 2024-12-26 Valo Health, Inc. Isoindolinone-containing parp inhibitors and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
US20090054407A1 (en) * 2005-04-19 2009-02-26 Kyowa Hakko Kogyo Co., Ltd. Nitrogen-containing heterocyclic compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054407A1 (en) * 2005-04-19 2009-02-26 Kyowa Hakko Kogyo Co., Ltd. Nitrogen-containing heterocyclic compound
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUGHES, T. V. ET AL.: "7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/ VEGF-R2 kinase inhibitors: Design, synthesis, and biological activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 18, 2008, pages 5130 - 5133, XP025407688, DOI: doi:10.1016/j.bmcl.2008.07.090 *

Also Published As

Publication number Publication date
WO2012047017A2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
WO2012047017A3 (en) 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2009155121A3 (en) Inhibitors of pi3 kinase
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
WO2014151871A3 (en) Jak2 and alk2 inhibitors and methods for their use
MX2011011335A (en) Inhibitors of pi3 kinase and / or mtor.
WO2012048129A3 (en) Inhibitors of polo-like kinase
MX2013011589A (en) Methods and compositions for treating parkinson's disease.
TR201906936T4 (en) Thienopyrimidine derivatives with inhibitory activity towards protein kinase.
MX2021011563A (en) 2,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including same.
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
MX2010006799A (en) Benzofuropyrimidinones as protein kinase inhibitors.
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MX2008013212A (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2011025167A3 (en) Pharmaceutical composition for preventing or treating cancer comprising 2,6-substituted 3-nitropyridine derivative compound or pharmaceutically acceptable salt thereof
WO2008131946A3 (en) Substituted amide derivatives
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11830902

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11830902

Country of ref document: EP

Kind code of ref document: A2